Over the past six months, Stryker’s shares (currently trading at $277.82) have posted a disappointing 20% loss, well below the S&P 500’s 12.8% gain. This may...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Check out the companies making headlines yesterday: Wendy's (NASDAQ:WEN): Fast-food chain Wendy’s (NASDAQ:WEN) rose by 5% on Wednesday after Yahoo Finance re...
What Happened? Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $1...
Stryker (NYSE:SYK) has outperformed the market over the past 20 years by 1.02% on an annualized basis producing an average annual return of 10.41%. Currently, Stryker has a market capitalization of $129.84 billion.
Stryker’s second quarter results met Wall Street’s revenue expectations, yet the market responded negatively, reflecting investor concerns about the company’...
Stryker (NYSE:SYK) reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year.
Chair and CEO Kevin Lobo said the co
